Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer s...
Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3 trial, as the KRAS field grows...
Author: Endpoints News
Read Original Article